Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective

Publikation: Beitrag in FachzeitschriftÜbersichtsartikel (Review)BeigetragenBegutachtung

Beitragende

Abstract

Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare oppurtonistic human pathogen associated mainly with intra-abdominal as well as skin and soft tissue infections. However, it has also been reported in association with more severe diseases such as pneumonia, intracerebral and ocular infections and endocarditis. In these cases the clinical courses are often associated with underlying, predisposing diseases and risk factors. For successful treatment of S. putrefaciens, a combination of appropriate local therapy, e.g. surgical treatment or drainage, and antibiotic therapy should be performed. Since multiple resistances to antibiotics are described, the results of the antimicrobial susceptibility testing must be considered for effective therapy as well. Furthermore, a main challenge in clinical practice is the accurate microbiological identification, and especially the correct differentiation between S. putrefaciens and S. algae. Under certain circumstances, Shewanella-infections can have severe, sometimes even fatal consequences. Therefore, we decided to present the current state of knowledge as well as further aspects with regard to future diagnostics, therapy and research.

Details

OriginalspracheEnglisch
Seiten (von - bis)1033639
FachzeitschriftFrontiers in cellular and infection microbiology
Jahrgang12
PublikationsstatusVeröffentlicht - 2 Feb. 2023
Peer-Review-StatusJa

Externe IDs

PubMedCentral PMC9933709
Scopus 85148336520

Schlagworte

Schlagwörter

  • Humans, Shewanella putrefaciens, Gram-Negative Bacterial Infections/microbiology, Anti-Bacterial Agents/therapeutic use, Shewanella, Soft Tissue Infections/drug therapy